BazEkon - Biblioteka Główna Uniwersytetu Ekonomicznego w Krakowie

BazEkon home page

Meny główne

Autor
Mishchenko Oksana (National University of Pharmacy, Kharkiv, Ukraine), Iakovlieva Larysa (National University of Pharmacy, Kharkiv, Ukraine), Adonkina Viktoriya (National University of Pharmacy, Kharkiv, Ukraine)
Tytuł
Pharmacoeconomic Evaluation of Fixed-Dose Triple Combination for Antihypertensive Therapy in Ukraine
Źródło
Journal of Health Policy and Outcomes Research, 2014, nr 1, s. 66-75, rys., tab., bibliogr. 30 poz.
Słowa kluczowe
Rynek farmaceutyczny, Leki
Pharmaceutical market, Drugs
Uwagi
summ.
Kraj/Region
Ukraina
Ukraine
Abstrakt
In Ukraine, the efficacy of treatment of arterial hypertension is only 19% in urban areas and 8 % in rural populations. The most important reasons of low efficiency of antihypertensive therapy (AHT) are a wrong choice of tactics of the patient management and low adherence of patients to treatment. The latter decreases with increasing amounts of prescribed drugs. One possible way to increase patients' compliance to treatment and the effectiveness of therapy is to use fixed-dose combinations (FDCs) of antihypertensive drugs (AHDs). The share of FDCs consumption (in terms of DDDs/1000/day) in Ukraine in the total structure of AHDs consumption is 25%, which is significantly less than the proportion of patients (60%), requiring combined AHDs. This is an indirect evidence of low compliance of Ukrainian patients to HD treatment and the need of pharmacoeconomic study of benefits of antihypertensive therapy using FDCs. As a result of pharmacoeconomic cost-effectiveness analysis it has been found that antihypertensive therapy in patients with moderate and severe AH using triple FDC Val+Aml+HCTZ compared with three dual FDC: Val+HCTZ, Val+Aml, Aml+HCTZ provides greater clinical efficacy (the number of patients with the achieved target level of blood pressure). This triple FDC Val+Aml+HCTZ has pharmacoeconomic benefits (greater cost efficiency), compared with only one dual FDC Val+HCTZ. This gives the opportunity to save money, presents additional advantages in efficiency and justifies benefits from its use by hypertensive patients in need of appointing the third AHD CCB amlodipine in addition to the existing dual one using valsartan and hydrochlorothiazide(original abstract)
Pełny tekst
Pokaż
Bibliografia
Pokaż
  1. Shalnova S. A., Balanova Yu. А., Konstantinov V. V. et al. Arterial hypertension: prevalence, awareness, administration of antihypertensive drugs and treatment efficacy among the population of the Russian Federation. Russian cardiological journal. 2006; 4: 45-50
  2. Arterial hypertension. Updated and adapted clinical guidelines based on evidence. - 2012. - 129 p. - Available from: http://www.dec.gov.ua/mtd/_ag.html
  3. Cohn J.N., Tognoni G., for the Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure N. Engl. J. Med. 2001; 345 (23): 1667-1675
  4. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative R. search Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor of calcium channel blocker vs diuretic: The antihypertensive and Lipid- Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA. 2002; 288(23): 2981- 2997
  5. Dahlöf B., Devereux R. B., Kjeldsen S. E. et al. Cardiovascular morbidity and mortality in the Losartan Intervention For End point reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002; 359(9311): 995-1003
  6. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA. 1991; 265: 3255-3264
  7. Hansson L., Zanchetti A., Carruthers S.G. et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension; principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998; 351: 1755-1762
  8. Mancia G., Fagard R., Narkiewicz K. et al. Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) 2013. European Heart Journal. 2013. Available from: http://eurheartj.oxfordjournals.org/
  9. Mourad J. J., Waeber B., Zannad F. et al. Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach. J Hypertens 2004; 22: 2379-2386
  10. The ALLHAT investigators. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA. 2002; 288 (23): 2981-2997
  11. Bertram P., Byington R., Curt D. et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation. 2000;102:1503-1510
  12. Nissen S. E., Tuzcu E. M., Libby P. et al. The CAMELOT/NORMALISE study. JAMA. 2004; 18: 2217-2226
  13. Dahlöf B., Sever P. S., Poulter N. R. et al. Prevention of cardiovascular events with an anti-hypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendr of lumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005; 366: 895-906
  14. Frans H.H. Leenen, Chuke E. Nwachuku, Henry R. Black et al. Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2006; 48: 374-384
  15. Julius S., Kjeldsen S. E., Weber M. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004; 363: 2022-2031
  16. Pfeffer M. A., McMurray J. J., Velazquez E. J. et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003; 349: 1893-906
  17. Wong M., Staszewsky L., Latini R. Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J Am Coll Cardiol. 2002; 40: 970-5
  18. Maggioni A. P., Latini R., Carson P. E. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J. 2005;149: 548-57
  19. Mochizuki S., Dahlöf B., Shimizu M. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet. 2007; 369: 1431-1439
  20. Sawada T., Yamada H., Dahlöf B., Matsubara H. Effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART. Eur Heart J. 2009; 30: 2461-2469
  21. Calhoun D. A., Lacourciere Y., Chiang T. Y., Glazer R. D. Triple antihypertensive therapy with amlodipine, valsartan and hydrochlorothiazide: a randomized clinical trial. Hypertension. 2009; 54: 32-39
  22. Anatomical therapeutic Chemical (ATC) classification index including defined daily doses (DDDs) for plain substances. WHO Collaborating Centre for Drug Statistics Methodology. 1999: 23-33
  23. Vorobyov P. A. Economic evaluation of the effectiveness of drug therapy (pharmacoeconomic analysis). Moscow 2000; 80.
  24. Ajay K. Gupta, Shazia Arshad, Neil R. Poulter. Compliance, Safety, and Effectiveness of Fixed-Dose Combinations of Antihypertensive Agents: A Meta-Analysis. Hypertension. 2010; 55: 399-407
  25. Elijovich F., Laffer C. A role for single-pill triple therapy in hypertension. Ther Adv Cardiovasc Dis. 2009; 3: 231-240
  26. Gradman A. H. Rationale for triple-combination therapy for management of high blood pressure. J Clin Hypertens (Greenwich). 2010a; 12: 869-878
  27. Gradman A. H., Basile J. N., Carter B. L. et al. Combination therapy in hypertension. J Am Soc Hypertens. 2010b; 4: 42-50
  28. Brixner D. I., Jackson K. C., Sheng X. et al. Assessment of adherence, persistence, and costs among valsartan and hydrochlorothiazide retrospective cohorts in free and fixed-dose combinations. Curr Med Res Opin. 2008; 24: 2597-2607
  29. Leonovа M. V., Belousov D. Yu., Steinberg L. L. et al. Results pharmacoepidemiological study of hypertension PIFAGOR III. System hypertension. 2010; 1: 8-15
  30. Fretheim A., Oxman A. D. International variation in prescribing antihypertensive drugs: Its extent and possible explanations. BMC Health Services Research. 2005; 5: 21-30
Cytowane przez
Pokaż
ISSN
2299-1247
Język
eng
URI / DOI
http://dx.doi.org/10.7365/JHPOR.2014.5.8
Udostępnij na Facebooku Udostępnij na Twitterze Udostępnij na Google+ Udostępnij na Pinterest Udostępnij na LinkedIn Wyślij znajomemu